Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics.
作者信息
Findlay John M, Bradley Kevin M, Gillies Richard S, Maynard Nicholas D, Middleton Mark R
机构信息
Oxford OesophagoGastric Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, UK.
出版信息
J Thorac Dis. 2017 Oct;9(10):3551-3552. doi: 10.21037/jtd.2017.09.54.
Abstract
摘要
相似文献
1
Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics.评估食管癌对新辅助治疗反应的挑战，以及联合PET-CT和多模态指标的潜力。
J Thorac Dis. 2017 Oct;9(10):3551-3552. doi: 10.21037/jtd.2017.09.54.
2
Loco-regional staging accuracy in oesophageal cancer-How good are we in the modern era?局部区域分期准确性在食管癌中的应用-在现代我们做得如何？
Eur J Radiol. 2017 Dec;97:71-75. doi: 10.1016/j.ejrad.2017.10.015. Epub 2017 Oct 23.
3
Can ¹⁸F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis.¹⁸F-氟脱氧葡萄糖正电子发射断层扫描能否预测食管癌患者对新辅助治疗的反应？一项荟萃分析。
Nucl Med Commun. 2011 Nov;32(11):1005-10. doi: 10.1097/MNM.0b013e32834a8366.
4
Relevance of [18F]fluorodeoxyglucose positron emission tomography-positive lymph nodes after neoadjuvant chemotherapy for squamous cell oesophageal cancer.新辅助化疗后 [18F]氟脱氧葡萄糖正电子发射断层扫描阳性淋巴结与食管鳞癌的相关性。
Br J Surg. 2013 Oct;100(11):1490-7. doi: 10.1002/bjs.9253.
5
Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer.新辅助化疗诱导的体积参数变化可准确预测食管癌患者切除术后的总生存。
Eur Radiol. 2016 Feb;26(2):311-21. doi: 10.1007/s00330-015-3860-7. Epub 2015 Jun 5.
6
Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using F-FDG PET/CT.利用 F-FDG PET/CT 预测和诊断新辅助放化疗后食管癌的间隔转移。
Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1742-1751. doi: 10.1007/s00259-018-4011-6. Epub 2018 Apr 16.
7
Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer - A propensity score matched analysis.新辅助放化疗对 cT3 期食管癌的预后影响——倾向评分匹配分析。
Eur J Cancer. 2014 Nov;50(17):2950-7. doi: 10.1016/j.ejca.2014.08.020. Epub 2014 Oct 9.
8
FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.18F-氟代脱氧葡萄糖正电子发射断层显像/X线计算机体层成像用于评估新辅助治疗后N2期非小细胞肺癌患者的可切除性。
Ann Nucl Med. 2016 Feb;30(2):114-21. doi: 10.1007/s12149-015-1038-7. Epub 2015 Nov 27.
9
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.新辅助放化疗后食管癌患者残留病灶的检测（preSANO）：一项前瞻性多中心、诊断队列研究。
Lancet Oncol. 2018 Jul;19(7):965-974. doi: 10.1016/S1470-2045(18)30201-8. Epub 2018 Jun 1.
10
18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.新辅助化疗下非小细胞肺癌的18F-FDG PET/CT：基于背景的自适应体积指标在预测组织病理学反应方面优于总病变糖酵解（TLG）和代谢肿瘤体积（MTV）
J Nucl Med. 2016 Jun;57(6):849-54. doi: 10.2967/jnumed.115.167684. Epub 2016 Jan 28.
本文引用的文献
1
Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.代谢性淋巴结反应作为新辅助治疗后食管癌的预后标志物。
Br J Surg. 2017 Mar;104(4):408-417. doi: 10.1002/bjs.10435. Epub 2017 Jan 17.
2
Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemotherapy: The Implications of Metabolic Nodal Response for Personalized Therapy.预测食管癌对新辅助化疗的病理反应：代谢性淋巴结反应对个体化治疗的意义。
J Nucl Med. 2017 Feb;58(2):266-275. doi: 10.2967/jnumed.116.176313. Epub 2016 Sep 15.
3
Current-day precision oncology: from cancer prevention, screening, drug development, and treatment - have we fallen short of the promise?当代精准肿瘤学：从癌症预防、筛查、药物研发到治疗——我们是否辜负了承诺？
Curr Opin Oncol. 2016 Sep;28(5):441-6. doi: 10.1097/CCO.0000000000000318.
4
Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy.食管癌对新辅助化疗的差异克隆进化
Nat Commun. 2016 Apr 5;7:11111. doi: 10.1038/ncomms11111.
5
A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.食管癌生存、治疗反应及分期的体细胞和生殖系DNA序列生物标志物的系统评价与荟萃分析。
Ann Oncol. 2015 Apr;26(4):624-644. doi: 10.1093/annonc/mdu449. Epub 2014 Sep 11.
6
Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now.新辅助放化疗后肿瘤退缩的病理分级：临床需求迫在眉睫。
J Clin Pathol. 2012 Oct;65(10):867-71. doi: 10.1136/jclinpath-2012-200958. Epub 2012 Jun 25.
7
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.可切除食管癌新辅助化疗或放化疗后的生存：更新的荟萃分析。
Lancet Oncol. 2011 Jul;12(7):681-92. doi: 10.1016/S1470-2045(11)70142-5. Epub 2011 Jun 16.
8
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.正电子发射断层扫描（PET）评估食管胃交界腺癌的早期代谢反应并指导治疗：MUNICON II期试验
Lancet Oncol. 2007 Sep;8(9):797-805. doi: 10.1016/S1470-2045(07)70244-9.
Zotero 插件